Impact of Cerebellar TMS on Brain and Cognitive Functions in Schizophrenia: a Pilot Study

Phase

N/A

Condition

Psychosis

Tourette's Syndrome

Schizotypal Personality Disorder (Spd)

Treatment

Transcranial Magnetic Stimulation

Clinical Study ID

NCT05389787

22-0171

Ages 18-60
All Genders

Study Summary

This is a single-site, sham-controlled, randomized trial in a total of 40 subjects between ages 18 and 60 years with schizophrenia. This study will investigate the effects of 4-week rTMS treatment on brain and cognitive functions in patients. Subjects will be randomized to one of the following arms:

Arm 1: Standard of Care (SOC) and active rTMS Arm 2: Standard of Care (SOC) and sham rTMS

Each participant will receive rTMS five days per week, for four consecutive weeks. Functional magnetic resonance imaging (fMRI) scans, clinical assessments, and cognitive tests will be performed at baseline, end of the 2nd week, and end of the 4th week.

Eligibility Criteria

Inclusion

Inclusion Criteria:

Male or female subjects 18 to 60 years of age
DSM-V diagnosis of schizophrenia spectrum disorders
Competent to provide informed consent

Exclusion

Exclusion Criteria:

Lifetime DSM-V diagnosis of an Axis-I disorder other than schizophrenia spectrumdisorders
Lifetime diagnosis of ataxia or other cerebellar disorders
Lifetime diagnosis of mental retardation, dementia, Alzheimer's disease, Parkinson'sdisease, Huntington's disease, or other neurodegenerative disorders
Any active general medical condition or CNS disease which can affect cognition orresponse to treatment
Substance dependence or abuse in the past six months
Seizure history
TMS within three months or ECT within six months
Pregnancy as indicated by self-report
MRI contraindications

Study Design